Upanovimab clinical trials
Also written SCTA01.
How each study uses upanovimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the upanovimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SCTA01
- 4
Studies by the year they started
5 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses upanovimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19Not yet recruitingPhase 2/3Sinocelltech Ltd.NCT04709328Written as SCTA01How we know
- The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19TerminatedPhase 2/3Sinocelltech Ltd.NCT04644185Written as SCTA01How we know
- A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19WithdrawnPhase 1/2Sinocelltech Ltd.NCT05156645Written as SCTA01 and SCTA01CHow we know
- Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese SubjectsCompletedPhase 1Sinocelltech Ltd.NCT04483375Written as SCTA01How we know
- The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive CareStatus unknownPhase 2/3Sinocelltech Ltd.NCT04683328Written as SCTA01How we know
Codes
What other systems call upanovimab · ClinicalTrials.gg INT001786
- MeSH (NLM) C000721007upanovimabOne source NLM
- UNII (FDA) 8E88WSA6X3UPANOVIMABConfirmed FDA, NLM
- NCI Thesaurus C175228UpanovimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000721007 | upanovimab | One source NLM |
| UNII (FDA) | 8E88WSA6X3 | UPANOVIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C175228 | Upanovimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.